ADMA Plasma Levels: Nitric Oxide and Cardiovascular Risk

Asymmetric dimethylarginine, usually called ADMA, is a naturally occurring molecule in your blood that interferes with nitric oxide production and, at elevated concentrations, is strongly linked to cardiovascular disease, kidney problems, and several other conditions. In healthy adults, plasma ADMA typically falls in the range of roughly 0.3 to 1.1 micromoles per liter, though the exact number depends heavily on the measurement method used. What makes ADMA interesting, and why researchers have spent more than two decades studying it, is that it appears to be not just a passive marker of trouble but a molecule that actively contributes to disease by choking off nitric oxide, the signal that keeps blood vessels relaxed and healthy.

Where ADMA Comes From

ADMA is not something you eat or absorb from the environment. It is produced inside your own cells as a byproduct of normal protein turnover. Certain enzymes called protein arginine methyltransferases attach small chemical groups (methyl groups) to the amino acid arginine while it is still built into proteins. When those proteins are eventually broken down and recycled, the modified arginine residues are released as free molecules into the cell and then into the bloodstream. Depending on exactly how the methyl groups are arranged, you get either ADMA, its mirror-image cousin symmetric dimethylarginine (SDMA), or a simpler version called monomethylarginine (MMA).¹ Of these, ADMA is the one that causes the most biological mischief, because it directly blocks the enzyme that makes nitric oxide.

How ADMA Disrupts Nitric Oxide

Nitric oxide is a small signaling molecule your blood vessels depend on. It relaxes the smooth muscle in artery walls, keeps blood pressure in check, discourages clot formation, and limits inflammation. Your body makes nitric oxide using an enzyme called nitric oxide synthase, which converts the amino acid L-arginine into nitric oxide. ADMA looks enough like L-arginine that it can sit in the enzyme’s active site and block the real substrate from getting in.² The result is less nitric oxide, stiffer arteries, and a vascular system that is more prone to damage. This is the central reason ADMA has attracted so much medical attention: it is not merely a bystander but a molecule that actively worsens vascular health.

Because ADMA competes with L-arginine, researchers often look at the ratio of L-arginine to ADMA rather than ADMA alone. A low ratio means ADMA is winning the competition and nitric oxide production is likely impaired. In studies of conditions like preeclampsia and sepsis, the L-arginine-to-ADMA ratio has been a stronger predictor of endothelial dysfunction than either molecule measured on its own.³ In sepsis patients, the ratio correlated with nitric-oxide-dependent blood flow in small vessels even after adjusting for kidney function.⁴

How the Body Clears ADMA

The main way your body gets rid of ADMA is through an enzyme called DDAH (dimethylarginine dimethylaminohydrolase), which breaks ADMA down into harmless products. There are two forms of this enzyme, DDAH1 and DDAH2, but knockout studies in mice have shown that DDAH1 is the one that actually does the heavy lifting. Mice missing DDAH1 had ADMA levels several times higher than normal in both plasma and tissues, and no measurable DDAH activity in any organ, even though DDAH2 was still present.⁵

Two organs are especially important for ADMA clearance. The liver breaks down ADMA exclusively through DDAH and also excretes some in bile. The kidneys use a combination of DDAH breakdown and direct urinary excretion.⁶ This dual-organ dependency explains why ADMA levels climb in both liver and kidney disease: lose either clearance pathway and the molecule accumulates in the blood.

Measuring Plasma ADMA

If you encounter ADMA on a lab report, the measurement method matters more than you might expect. The two main techniques are HPLC (a chromatography-based method) and ELISA (an antibody-based immunoassay). A large meta-analysis pooling data from 66 studies and over 5,500 healthy adults found that the two methods give systematically different numbers. The average ADMA concentration reported by HPLC was about 0.71 micromoles per liter, while ELISA gave a mean of about 0.57 micromoles per liter. The reference ranges differed accordingly: roughly 0.34 to 1.10 by HPLC and 0.25 to 0.92 by ELISA.⁷

Direct comparison studies between the two methods have found worryingly poor agreement. In one head-to-head evaluation of 55 serum samples, there was essentially no correlation between HPLC and ELISA results. The HPLC method had much tighter precision, with variability under 5% between runs, while the ELISA’s variability ranged from 9% to 19%.⁸ The practical takeaway is that you cannot meaningfully compare an ADMA result from an HPLC lab to one from an ELISA lab. If you are tracking ADMA over time, the same method should be used each time.

Cardiovascular Risk and Coronary Artery Disease

The connection between elevated plasma ADMA and heart disease is one of the most replicated findings in this area. In the AtheroGene Study, patients with established coronary artery disease were followed over time. Those whose baseline ADMA fell in the top third had roughly two-and-a-half times the risk of a future cardiovascular event compared with those in the bottom third, and that association held after adjusting for conventional risk factors. When researchers built prediction models that included ADMA alongside other biomarkers like BNP and C-reactive protein, ADMA emerged as one of the two strongest predictors.⁹

A separate study of nearly 1,000 patients referred for coronary angiography found a stepwise increase in plasma ADMA as coronary disease severity worsened: patients with significant blockages had higher levels than those with moderate disease, who in turn had higher levels than those with clean arteries. In multivariate analysis, ADMA independently predicted the presence of significant disease and also predicted long-term adverse outcomes.¹⁰ Work using optical coherence tomography, which visualizes plaques inside coronary arteries, has further linked higher ADMA levels to the presence of vulnerable, rupture-prone plaque features like intra-plaque lipid and calcification.¹¹

Blood Vessel Stiffness and Endothelial Function

Even before overt heart disease develops, ADMA appears to impair how well blood vessels respond to changes in blood flow. Two population-based studies, one involving young Finnish adults and another in subjects at low cardiovascular risk, found that higher plasma ADMA correlated with poorer flow-mediated dilation, which is the standard non-invasive test of endothelial health. In the Finnish study, the association survived adjustment for age, sex, kidney function, and traditional risk factors.¹² In the low-risk cohort, ADMA turned out to be one of only three independent predictors of vessel dilation, alongside artery diameter and fasting insulin.¹³ These findings suggest ADMA is relevant to vascular health well before anyone develops symptoms.

The Kidney Connection

Kidney disease and ADMA have an unfortunate feedback relationship. As kidney function declines, the organ’s ability to clear ADMA through both enzymatic breakdown and urinary excretion drops, so plasma levels rise. Patients with moderate chronic kidney disease (stages 3–4) show significantly higher mean ADMA concentrations than healthy individuals.¹⁴ Among people with diabetic kidney disease specifically, each standard-deviation increase in plasma ADMA was associated with about a 30% higher risk of atherosclerotic cardiovascular events.¹⁵

Researchers have proposed that the buildup of ADMA (and its less-studied relative L-NMMA) after kidney failure is one reason people with chronic kidney disease have such disproportionately high rates of heart attacks and strokes.¹⁶ In the most advanced kidney disease, especially patients on dialysis, ADMA is recognized as a uremic toxin and an independent predictor of cardiovascular death.¹⁷ Interestingly, ADMA and SDMA together can predict the risk of poor kidney outcomes with strong discriminative ability, raising the possibility that plasma methylarginine testing could one day help stratify which kidney patients need the most aggressive monitoring.¹⁸

ADMA in Liver Disease

Because the liver is one of the two main organs responsible for clearing ADMA, liver disease predictably leads to rising plasma levels. The correlation tracks with disease severity. In patients with alcoholic cirrhosis, those with decompensated (more advanced) disease had ADMA levels roughly twice as high as patients with compensated cirrhosis or healthy controls, and ADMA correlated with the clinical severity score.¹⁹ The likely mechanism is that severe inflammation and oxidative stress in a failing liver directly damage DDAH, crippling the enzyme’s ability to break down ADMA. Similar elevations have been documented in acute liver failure and alcoholic hepatitis.²⁰

Pulmonary Hypertension

The lungs have their own nitric oxide system that helps keep pulmonary blood pressure low. When ADMA disrupts that system, pulmonary vascular resistance can rise. In both animal models and patients with idiopathic pulmonary arterial hypertension, marked increases in plasma ADMA and SDMA levels have been found, along with elevated levels of dimethylated proteins in lung tissue.²¹ A proof-of-concept experiment went further: infusing ADMA into healthy volunteers raised their pulmonary vascular resistance by roughly 40% and reduced stroke volume.²² In children with congenital heart disease, plasma ADMA correlated with both pulmonary arterial pressure and pulmonary vascular resistance, suggesting it might be useful for tracking disease stage.²³

Preeclampsia

Pregnancy normally involves massive expansion of blood volume and relaxation of blood vessels, both of which depend on nitric oxide. Several studies have found that women who go on to develop preeclampsia have higher plasma ADMA levels than those with uncomplicated pregnancies. In one study, pregnant women with evidence of poor placental blood flow had ADMA levels roughly three times those of women with normal flow, and women in this group who subsequently developed preeclampsia had the highest levels of all.²⁴ Other work has confirmed that ADMA is significantly higher in preeclamptic women and that DDAH activity in the placenta is severely reduced, potentially explaining why ADMA accumulates.²⁵ ADMA levels also appear to rise through normal late pregnancy, but in preeclampsia the increase is steeper and begins earlier.²⁶

Stroke and Critical Illness

After an ischemic stroke, plasma ADMA rises. The increase appears driven by a combination of heightened protein methylation, oxidative stress, and reduced DDAH activity in the post-stroke period.²⁷ Timing matters: in one study tracking stroke patients over their first week, ADMA levels at day 3 above about 0.57 micromoles per liter and at day 7 above about 0.53 micromoles per liter predicted an unfavorable clinical outcome.²⁸

In the intensive care unit, ADMA has an even more dramatic track record. Among critically ill patients, those in the highest quartile for plasma ADMA had a 17-fold increased risk of dying in the ICU compared with those in the lowest quartile.²⁹ In sepsis specifically, where the balance between nitric oxide overproduction and endothelial dysfunction is a central feature of the disease, elevated ADMA has been linked to mortality across multiple studies.³⁰

Insulin Resistance and Metabolic Health

The link between ADMA and metabolic problems runs in both directions. Conditions that feature oxidative stress, including high blood sugar, high cholesterol, and high blood pressure, tend to impair DDAH activity and push ADMA levels up.³¹ But ADMA itself also appears to worsen insulin signaling. In muscle cell experiments, exposing cells to ADMA suppressed the chain of signals that normally responds to insulin and significantly reduced glucose uptake.³² This creates the possibility of a vicious cycle: metabolic disease raises ADMA, and elevated ADMA makes metabolic disease worse.

ADMA and SDMA Compared

SDMA, the structural mirror image of ADMA, is often measured alongside it. For years SDMA was considered biologically inert, but that view has changed. While ADMA is the stronger inhibitor of nitric oxide synthase and the more consistent cardiovascular risk predictor, SDMA has emerged as a remarkably reliable marker of kidney function, outperforming ADMA in that specific role. In patients with end-stage kidney disease on dialysis, SDMA levels climb higher than ADMA levels, largely because SDMA depends more on renal excretion. Both molecules are now recognized as uremic toxins and independent risk markers for cardiovascular events and mortality in kidney disease populations.³³

Lowering ADMA With Statins

Given ADMA’s role in vascular disease, the natural question is whether anything can lower it. Statins, already the most widely prescribed drugs for cardiovascular risk reduction, appear to do so. A meta-analysis of randomized controlled trials found that statin treatment over periods of 4 to 48 weeks significantly reduced plasma ADMA compared with placebo.³⁴ An earlier meta-analysis broke the effect down by statin type and found that water-soluble statins like rosuvastatin and pravastatin drove most of the reduction, while fat-soluble statins like simvastatin and atorvastatin had a weaker effect that did not clearly differ from placebo.³⁵ Whether the ADMA-lowering action of statins contributes to their cardiovascular benefit, or is simply a side effect, remains unclear.

Exercise and Lifestyle Changes

Regular aerobic exercise consistently lowers plasma ADMA in intervention studies. In postmenopausal women, an exercise training program reduced ADMA and simultaneously improved arterial compliance, with the size of the ADMA drop correlating with the size of the vascular improvement.³⁶ A study in middle-aged and older adults of both sexes found that aerobic training decreased ADMA, increased nitric oxide metabolites, and improved the ratio between the two, and that the improvement in this ratio correlated with reduced arterial stiffness.³⁷

The benefits are not limited to exercise alone. A 12-week combined lifestyle modification program in overweight and obese men that included dietary changes and physical activity led to significant reductions in both ADMA and arterial stiffness, and the two decreases tracked together.³⁸ These findings suggest that some of the vascular benefits of exercise and weight loss are mediated, at least in part, through ADMA reduction.

ADMA Across the Lifespan

Plasma ADMA is not constant from birth to old age. In a study tracking dimethylarginine levels from newborns through adolescence, ADMA concentrations were highest in neonates and declined progressively during childhood.³⁹ The reasons for high neonatal levels are not fully worked out, but rapid cell turnover and high rates of protein methylation during development are plausible contributors. This pattern is worth knowing if ADMA is measured in pediatric patients: the reference ranges established in adults do not apply to children, and a value that looks elevated in an adult may be normal for a newborn.

ADMA and Brain Health

Beyond the well-studied cardiovascular and renal connections, emerging work links ADMA to neurodegenerative processes. In animal models of cerebral amyloid angiopathy, a condition where amyloid proteins accumulate in brain blood vessels, ADMA treatment worsened blood-brain barrier dysfunction, reduced the density of tiny vessels in the brain, and aggravated cognitive impairment.⁴⁰ The implication is that ADMA’s vascular damage extends to the brain’s microcirculation, potentially contributing to the kind of small-vessel disease that underlies vascular dementia. This research is still in its early stages and the clinical relevance for humans is not settled, but it adds another dimension to why chronically elevated ADMA may matter beyond the heart and kidneys.